Table 1.
Body weight, SBP, MAP and HR at the end of the 4th week.
Figure 1.
Effects of PVN microinjection of saline and three doses of Ang-(1–7) (0.03, 0.3 and 3 nmol) on the baseline RSNA and MAP and CSAR.
The CSAR was evaluated by the RSNA and MAP responses to epicardial application of capsaicin (1 nmol). Values are mean ± SE. * P<0.05 compared with saline. † P<0.05 compared with Sham. n = 6 for each group.
Figure 2.
Representative recordings showing the effects of PVN microinjection of saline and Ang-(1–7) (3 nmol) on the CSAR in Sham and 2K1C rats.
The CSAR was evaluated by the RSNA and MAP responses to epicardial application of capsaicin (1 nmol).
Figure 3.
Effects of PVN microinjection of saline, Ang-(1–7) (3 nmol), A-779 (3 nmol), A-779+Ang-(1–7) on the baseline RSNA and MAP and CSAR.
The CSAR was evaluated by the RSNA and MAP responses to epicardial application of capsaicin (1 nmol). Values are mean ± SE. * P<0.05 compared with saline. † P<0.05 compared with Sham. ‡ P<0.05 compared with Ang-(1–7) alone. n = 6 for each group.
Figure 4.
Mas receptor protein expression (A & B), Ang-(1–7) level (C) and ACE2 activity (D) in the PVN in Sham and 2K1C rats.
RFU, relative fluorescence units. Values are mean ± SE. * P<0.05 compared with Sham rats. n = 5 for each group.
Figure 5.
Effects of the PVN microinjection of saline, SQ22536 (2 nmol), db-cAMP (1 nmol) and Rp-cAMP (1 nmol) on the baseline RSNA and MAP and CSAR.
The CSAR was evaluated by the RSNA and MAP responses to epicardial application of capsaicin (1 nmol). Values are mean ± SE. * P<0.05 compared with saline. † P<0.05 compared with Sham. n = 6 for each group.
Figure 6.
Effects of the PVN treatment with saline, SQ22536 (2 nmol), db-cAMP (1 nmol) and Rp-cAMP (1 nmol) on the RSNA, MAP and CSAR responses to Ang-(1–7) (3 nmol).
The CSAR was evaluated by the RSNA and MAP responses to epicardial application of capsaicin (1 nmol). Values are mean ± SE. * P<0.05 compared with saline. † P<0.05 compared with Sham. n = 6 for each group.